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The advent of on-line multidimensional liquid chromatography-mass spectrometry has
significantly impacted proteomic analyses of complex biological fluids such as plasma.
However, there is general agreement that additional advances to enhance the peak capacity of
such platforms are required to enhance the accuracy and coverage of proteome maps of such
fluids. Here, we describe the combination of strong-cation-exchange and reversed-phase liquid
chromatographies with ion mobility and mass spectrometry as a means of characterizing the
complex mixture of proteins associated with the human plasma proteome. The increase in
separation capacity associated with inclusion of the ion mobility separation leads to generation
of one of the most extensive proteome maps to date. The map is generated by analyzing
plasma samples of five healthy humans; we report a preliminary identification of 9087 proteins
from 37,842 unique peptide assignments. An analysis of expected false-positive rates leads to
a high-confidence identification of 2928 proteins. The results are catalogued in a fashion that
includes positions and intensities of assigned features observed in the datasets as well as
pertinent identification information such as protein accession number, mass, and homology
score/confidence indicators. Comparisons of the assigned features reported here with other
datasets shows substantial agreement with respect to the first several hundred entries; there is
far less agreement associated with detection of lower abundance components. (J Am Soc
Mass Spectrom 2007, 18, 1249–1264) © 2007 American Society for Mass SpectrometrySince Wilkins and coworkers coined the term “pro-teomics” in 1994 [1], there has been a significanteffort to develop platform technologies for pro-
teomic analyses [2] (for proteomic platform technology
development information, see the reviews and refer-
ences therein). Although spectacular progress has been
made, analytical strategies for characterizing complex
mixtures of proteins found in various tissues and bio-
logical fluids are still at an early stage. Even seemingly
simple questions are often difficult to definitively an-
swer, such as: how many and what proteins are
present? In what quantities? Where and when do they
exist in the cell, organism, or population? In the work
presented below, we describe the generation of a pro-
teome map by a multidimensional analysis that com-
bines strong-cation-exchange (SCX), reverse-phase liq-
uid chromatography (LC), ion-mobility spectrometry
(IMS), and mass spectrometry (MS). We focus on a
readily available biological fluid—human blood
plasma. As discussed below, comprehensive plasma
proteome characterization is arduous by any technique.
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doi:10.1016/j.jasms.2007.04.012Our study is no exception to this. We summarize our
findings in the form of a catalogue that contains 9087
protein entries; 2928 of which are high-confidence as-
signments, anticipated to be signals that should be
reproducibly discernable with this approach. This cat-
alogue is consistent with previous measurements for
many of the more abundant species (the first several
hundred proteins in our summary); there is much less
consensus about lower-abundance proteins that we
report (many have not been observed previously, and
many that have been reported by others are not ob-
served in this study).
In considering how many proteins are detectable in
plasma, it is worthwhile to define what we mean by
characterization of the plasma proteome. About 40
highly-abundant proteins found in plasma are referred
to as classical plasma proteins (those with known
circulatory functions) [3]; however, consideration of
other sources such as tissue leakages suggests that105
different proteins may be present. Inclusion of splice
variants suggests 500,000 different protein forms and
perhaps 107 immunoglobulin sequences [3]. The ap-
proach taken below, to include an additional IMS
separation dimension, increases the available experi-
mental peak capacity (compared with other multidi-
mensional methods). This experimental measurement
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extremely complex mixtures [4]. However, the assign-
ments are based on parent and fragment ion mass
spectrometry (MS) results that are interpreted using the
Swiss-Prot nonredundant human proteome database
[5]. At the time of these experiments the database
contained 11,851 protein sequences. Thus, our catalogue
is restricted to this number of possible assignments.
The consideration of the large number of possible
species only captures a part of the analytical problem.
Abundant components such as the albumin, immuno-
globulin, transferrin, apolipoprotein, haptoglobin, com-
plement and fibrinogen proteins may be present at
mg-mL1 levels. It is estimated that the 22 most abun-
dant proteins comprise 99% of the total protein content
by mass [6], whereas species such as interleukins,
involved in immune response [7], appear as minor
constituents, present at pg-mL1 levels [3]. Thus, the
range of concentrations spans at least nine orders of
magnitude. Overall, these considerations help rational-
ize why a comprehensive characterization by existing
analytical methods is essentially intractable.
It is paradoxical that a system that cannot be defini-
tively defined has become a benchmark for assessing the
capabilities of new instrumentation. The employment of a
set of questions (e.g., How many? Which proteins can be
detected in plasma?) as a standard measure of the merits
of new technology, to which there is no known answer
(and moreover, which must vary from sample to sample)
is driven by the potential clinical importance of this
sample. One of the advantages of including IMS is that it
reduces chemical noise (interferences of signals that arise
in congested spectra [8]); this often allows low-abundance
components to be detected, even in the presence of more
abundant species [9]. Although we aim to improve cov-
erage by taking this approach, we recognize that many of
the entries that are included in our map must be false
assignments. In an effort to understand the threshold for
truly discernable signals, we compare our assigned pro-
tein list (based on matching the Swiss-Prot database) to a
list that is generated by assigning our datasets to the same
database having inverted amino acid sequences. This
provides a measure of the rate of random assignments but
does not illuminate which assignments are expected to be
false. Future experiments will be necessary to corroborate
those features that are reproducibly detected.
Although most of the components that exist in
plasma may not have been identified, some features are
definitively known. Studies using two-dimensional gel
electrophoresis provided much of the early knowledge
of the more abundant plasma proteins [10 –12]. Analysis
by this method can be traced back to the 1970s [3, 13,
14], and 60 proteins (primarily the classical plasma
proteins) had been identified by 1992 [15]. In the last
decade, shotgun proteomics utilizing LC and SCX-LC
combined with MS detection and database assignment
techniques emerged as a powerful means of character-
izing complex protein mixtures [16 –18]. These methods
dramatically increased the number of observable pro-teins (and also reduced the time for analysis) [6, 19 –22].
It is now common to identify hundreds of proteins from
plasma for a single sample [23–25]. Several studies
report even greater coverage [21, 24 –26].
With such rapid progress in characterizing a sample
about which so little is known, it is important to
develop standard procedures for comparing findings.
Many factors limit the comparison of plasma proteome
analyses, including: differences in methods of sample
procurement and preparation [25, 27–30]; incomplete
sampling associated with ion selection and dissociation
methods associated with MS analysis [21, 31–37]; limi-
tations in instrumental dynamic range [21, 38, 39]; early
developmental stage of the algorithms and databases
used for protein assignment [40, 41]; as well as actual
differences in composition between plasma samples [3,
9, 15, 21, 39]. An impression about the extent of the
variability that exists can be gleaned from Anderson et
al.’s 2004 summary of the reported literature from four
sources [15]. This summary included a single nonre-
dundant protein list of 1175 unique proteins; however,
only 46 were detected from all four different sources.
More recently, a core dataset of 3020 plasma proteins
was generated by a cooperative effort known as the
plasma proteome project [directed by the Human Pro-
teome Organization, (HUPO)] [25]. This more compre-
hensive dataset is a compilation of results from 35
laboratories (and other analytical groups) and allows
for statistical evaluation by others [42]. Of those pro-
teins reported in the plasma proteome project summary
(the 3020 core dataset), 316 are found in Anderson’s
1175 nonredundant list [25].
In 2006, our group reported a method designed to
increase the throughput of comprehensive plasma pro-
teome analyses [9]. In that work, we introduced IMS
separation to reduce the total time required for two-
dimensional LC analysis. We found evidence for 438
proteins. Here, we extend the 2006 study by carrying out
a more extensive two-dimensional LC analysis (and inclu-
sion of an abundant protein removal step) on samples
from five healthy (normal) individuals. This more com-
prehensive effort increases proteome coverage.
The present work involving IMS measurements
builds on advances in instrumentation and theory.
During the last 15 y, fundamental work that makes the
present work possible has been done, including: cou-
pling of new ion sources to mobility instruments [43–
49]; improvements in ion focusing [47, 50 –53], detection
limits [53–55], and instrumental resolution [56 –58];
methods for predicting mobilities [59 – 62]; as well as
comparing measurements with mobility calculations
[63– 65] (for trial geometries generated by theory) to
characterize ion structure [66 – 68]. Although we have
not included such an analysis here, the ability to check
assignments by comparison of experimental and theo-
retical mobilities is likely to have substantial value in
reducing false assignments. The format of the map that
is presented includes experimental parameters, as well
as drift times, ion charge states, and sequences, so that
See t
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the future.
One final point is important. Although we report
9087 proteins, of which 2928 meet our criteria as high-
confidence assignments, we believe that at this early
stage the best use of these data is as a means of testing
new analytical technologies. It is difficult to resist the
temptation to check to see if potential disease markers
found from analysis of tissues are detectable in plasma;
however, in our opinion, any such comparison (with
this or other extensive plasma lists) should be done
cautiously.
Experimental
General
A schematic showing the overall process associated
with characterizing the plasma proteome is provided as
Figure 1. The individual steps in this process, described
in detail below, are as follows: (1) acquire plasma
proteins from blood samples and enzymatically digest
this mixture to produce tryptic peptides; (2) fractionate
the mixture of peptides using SCX; (3) record triplicate
analyses of each fraction using a home built LC-IMS-MS
setup; (4) find all peaks associated with precursor ion
MS and fragment ion MS datasets; (5) compare all MS
peaks against a database of expected protein sequences
for identification; and (6) cull together information
Figure 1. Schematic representation of the ex
proteome map. In many ways this analysis is
difference is found in the inclusion of a split-fie
modulation for generation of fragment spectra.about interpreted peaks to produce the proteome map.With the exception of LC columns and pumping sys-
tems (Step 2 and partially Step 3) and the algorithms
used for protein (all of Step 5), all instrumentation and
software are home built.
We often refer to multidimensional measurements
or datasets as nested. This term was chosen in the first
paper that describe IMS-MS measurements that took
advantage of the fact that flight times in the evacu-
ated MS instrument are much shorter than the time
required for ions to drift through the buffer gas (in
the IMS experiment). Such a case has a theoretical
advantage compared with scanning (or selected ion)
approaches in that all components are (in theory)
subjected to the same analysis. In the present work,
the time scales are such that the MS measurement
(s) is nested within the IMS separation (ms); the IMS
separation is nested within the LC measurement (s);
and, the LC measurement is nested within the SCX
separation.
Acquisition of Plasma Samples
Whole blood (2 mL) was drawn by a trained phleboto-
mist using standard venipuncture techniques. Ethylene
diamine tetra-acetic acid (Vacutainer no. 367899, Bec-
ton, Dickinson & Company, Franklin Lakes, NJ) was
used as the anticoagulant agent. The blood sample was
then centrifuged at 4000 rpm to obtain platelet poor
ental protocol used to generate the plasma
ogous to other SCX-LC-MS/MS methods. The
ift tube for IMS separation and the use of field
ext and references therein for details.perim
anal
ld drplasma. Blood sample collection and analyses have
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proved institutional review board protocols [69].
Depletion of Abundant Proteins
Abundant proteins are depleted using the Agilent high
capacity multiple affinity removal system (MARS; Agi-
lent Technologies, Inc., Palo Alto, CA), which consists
of an LC column (4.6  100 mm) that utilizes antigen-
antibody interactions to remove six abundant plasma
proteins: albumin, IgG, IgA, transferring, haptoglobin,
and antitrypsin [70]. From 500 L of plasma 90 L
aliquots are diluted with the addition of 270 L of
buffer A and filtered through a 0.22 m spin filter
(Agilent) to remove particulates before injection onto
the column. A high-pressure LC (600 series pump; 2487
dual  detector, Waters, Inc, Milford, MA) is operated
as follows: 100% buffer A at a flow rate of 0.5 mL-min1
for 10 min followed by 100% B for 7 min at 1.0
mL-min1 to elute the bound fraction containing the six
abundant proteins. The flow-through fraction contain-
ing low-abundance proteins is collected between 2.0
and 6.0 min. The column is regenerated by equilibrating
with buffer A for 11 min at a flow rate of 1.0 mL-min1.
Elution of proteins is monitored at   280 nm. Succes-
sive aliquots are introduced onto the MARS column
until the original 500 L sample is consumed.
Enzymatic Digestion of the Plasma Protein
Mixture to Create Mixtures of Peptides
Mixtures of proteins are digested with trypsin to pro-
duce mixtures of peptides. This approach is referred to
as a bottom-up approach and is essentially done to make
it possible to generate ions that will produce useful
precursor-ion and fragment-ion datasets. To obtain
tryptic peptides, the flow-through fraction is concen-
trated with a 4.0 mL Vivaspin 5 K Da MWCO mem-
brane concentrator (Agilent Technologies). A subse-
quent Bradford assay experiment is performed and
typically samples are found to contain 4 mg total
plasma protein. The sample is then added to 10.0 mL 0.2
M Tris buffer containing 8 M urea along with 10.0 mM
CaCl2. Disulfide bonds are reduced by addition of
dithiothreitol (DTT) at a molar ratio of 40:1 (DTT:
protein) and incubated at 37 °C for 2 h. After reduction,
the sample is cooled to 0 °C on ice and iodoacetamide
(IAM) is added at a molar ratio of 80:1 (IAM:protein)
and left for another 2 h in darkness. Excess cysteine
(40-fold excess) is added at room temperature to react
with any residual DTT and IAM for 30 min. The sample
is then diluted with 0.2 M Tris buffer (pH  8.0) until
the urea concentration is 2 M. Finally, 2% (wt/wt)
TPCK-treated trypsin (Sigma-Aldrich) is added to the
solution and digestion is allowed to occur for 24 h at
37 °C. The resulting tryptic peptides are desalted with
an Oasis HLB cartridge (Waters Inc.) and dried on a
centrifugal concentrator.Strong-Cation Exchange (SCX) Fractionation
The separation column (100  2.1 mm) is packed with 5
m 200 Å Polysulfethyl A (PolyLC Inc., Columbia, MD)
and installed on the same LC system as described
above. Dried peptides are reconstituted in 500 L buffer
SCX1 and passed through a 0.22 m spin filter before
being loaded onto the column. The flow rate is kept at
0.2 mL min1, and the sample is fractionated using a
two buffer system [buffers SCX1 and SCX2 were pre-
pared as follows: SCX1. 5 mM KH2PO4 in 75:25 water:
acetonitrile (pH  3) and SCX2. 5 mM KH2PO4, 0.35 M
KCl in 75:25 water:acetonitrile (pH  3)]. The following
gradient is employed: 0% buffer SCX2 for 5 min, 0% to
40% buffer SCX2 in 40 min, 40% to 80% buffer SCX2 in
45 min, 80% to 100% buffer SCX2 in 10 min, 100% buffer
SCX2 for 10 min, 100% to 0% buffer SCX2 in 15 min, and
0% buffer SCX2 for 10 min. Eluting peptides are mon-
itored at both 210 and 280 nm. Eluent is collected
manually over 1-min intervals with a 96-well plate.
Individual wells are pooled into eight fractions based
on the absorbance profile of the eluted peptides. All
fractions are desalted with HLB cartridges and dried
before LC-IMS-MS analysis.
Nanoflow Reverse-Phase LC
The nanoflow reverse-phase LC separation is carried
out with an Agilent 1100 Series CapPump (Agilent
Technologies) equipped with a homemade nanocolumn
(75 m 150 mm) as well as a packed trapping column
(100 m  15 mm). The tip at the end of the 75 m
fused capillary (Polymicro Technology LLC, Phoenix,
AZ) is pulled with a microflame torch and packed with
a methanol slurry of 5 m, 100 Å Magic C18AQ
(Microm BioResourses Inc., Auburn, CA) at a constant
pressure (1000 psi). The trapping column (1.5 cm) is
packed in a 100 m capillary with an integral frit (New
Objective Inc., Woburn, MA) using a slurry of 5 m, 200
Å Magic C18. The trapping column is employed before
the analytical column and used to preconcentrate and
desalt the sample. Dried peptides are reconstituted in
HPLC water and an aliquot of 10 L of sample is
introduced onto the column. A binary gradient with
Solvent A (97% H2O, 3% ACN, and 0.1% formic acid)
and Solvent B (3% H2O, 97% ACN, and 0.1% formic
acid) is employed as the mobile phase with the follow-
ing gradient sequence: Solvent B is ramped up from 6%
to 30% in 100 min and then increased to 38% over 20
min. Subsequently, Solvent B is rapidly increased to
90% over 10 min and maintained for 15 min to elute the
highly retained species. Finally the gradient is changed
to 0% Solvent B immediately and held for another 15
min to equilibrate the column.
IMS-MS Measurements
The IMS-MS instrument shown in Figure 1 is similar to
others described in detail elsewhere [9, 71, 72]. How-
1253J Am Soc Mass Spectrom 2007, 18, 1249–1264 MAPPING THE HUMAN PLASMA PROTEOME BY SCX-LC-IMS-MSever, there are some differences that address issues
associated with ion storage and transmission in the
mobility device. An ion funnel (hour-glass geometry),
similar to one described by Smith and coworkers, [50,
51, 53] has been employed for ion accumulation before
the drift tube. This geometry is employed to increase
storage capacity and overall sensitivity [53]. Addition-
ally, a second ion funnel has been incorporated near the
exit region of the drift tube before the TOF source
region to improve ion transmission [53].
The overall experimental sequence associated with
the IMS-TOF analysis is as follows. Electrosprayed
peptides are introduced into an hour-glass ion funnel
where ions are stored and pulsed into the drift tube for
mobility separation. The drift tube utilizes a split-field
design [71] that allows either transmission or fragmen-
tation of precursor ions depending on the applied
voltages at the drift exit region. The first field region is
70.4 cm long. Ions drift through 3.20  0.05 torr of 300K
N2:He buffer gas (1:16 blend) under the influence of a
uniform field (12.6 V cm1) and are separated based on
differences in their mobilities. As has been described
previously, drift times are highly reproducible [9, 66,
67]. Ions with more compact structures tend to have
higher mobilities (undergo fewer collisions with the
buffer gas) than ions with extended structures [66 – 68,
73]. Additionally, ions with higher charge states typi-
cally have higher mobilities than ions with low charge
states because they experience a larger drift force [74,
75].
The second drift region is relatively short (1 cm
long). The electric field in this region is alternated
between conditions that favor precursor ion transmis-
sion or fragmentation via collision-induced dissociation
(CID) [71]. Modulation is achieved with fast, high-
voltage operational amplifiers (Apex Microtechnology,
Tucson, AZ). Upon exiting the drift tube, mobility
dispersed ions are extracted orthogonally into the
source region of a reflectron time-of-flight MS instru-
ment for mass to charge (m/z) analysis.
Nomenclature for Peak Positions
and Data Analysis
The positions of individual peaks are determined using
an algorithm written in-house and can be described by
a nomenclature that incorporates the concept of the
nested measurement [76]. We report LC retention times
(tR), IMS drift times (tD), and MS m/z values (obtained
from flight times) for features observed in the dataset as
tR[tD(m/z)] in units of min[ms(m/z)]. SCX information is
included as tSCX, referring to the SCX fraction number
such that any peak can be defined as tSCX{tR[tD(m/z)]}.
We begin data analysis by processing the raw data
with software developed in-house to determine the
positions and intensities associated with peaks found in
the multidimensional space. Once a multidimensional
peak and intensity list has been generated, m/z values(associated with modulated measurements) having
peaks with identical values of tSCX, tR, and tD are
grouped together to effectively assemble parent and
fragment mass spectra. These data are then converted
into DTA files (SEQUEST, Thermo Finnigan, Waltham,
MA), which are submitted for query against the Swiss-
Prot protein database (release 20050201) using the suite
of MASCOT software (Matrix Science Ltd. London, UK)
[77, 78]. Queries that lead to scores that are above the
extensive homology or identity threshold are saved as
possible peptide assignments. These preliminary as-
signments are subjected to a set of additional criteria,
including the number of fragments observed for a given
ion type (such as b- or y-series ions) and information
about the fragment ion mass accuracy that is used to
remove obvious false positives. The peak positions and
intensities of those peptides that meet the assignment
criteria are compiled into a searchable database (the
initial proteome map). The entire data analysis is auto-
mated and has been optimized with the use of a 24 node
dual CPU (IBM e326) cluster.
Results and Discussion
Considerations Associated with Inclusion
of an IMS Separation Dimension
It is worthwhile to summarize some of the strengths
and weaknesses associated with including an IMS sep-
aration dimension for plasma proteome analysis. From
an experimental perspective, the increase in peak capac-
ity that is obtained occurs on a very rapid time scale
(ms) such that there is no increase in the time associated
with LC-IMS-MS data acquisition compared with
LC-MS. The increase in peak capacity reduces spectral
congestion and leads to an increase in the ability to
resolve peaks. Thus, from the perspective of profiling it
is an attractive approach.
The modulation method that we employ allows the
generation of fragment ions for distributions of ions in
a parallel fashion [71, 79]. In some ways this is an
advantage as well. For example, in cases where many
species co-elute from the LC column, there may not be
adequate time to select all of them for MS/MS analysis.
Also, MS/MS methods run into difficulties in selecting
low-intensity features that are near (or below) the
baseline of the parent ion MS measurement. The mod-
ulated approach that we employ makes it possible to
observe many of these types of ions that would be
missed with conventional MS/MS methods. This said,
the dearth of a formal MS selection step for fragment
ion analysis is often a significant disadvantage. For such
complex mixtures, it is often the case that multiple
precursor ions are present even after SCX, LC, and IMS
separations, and in such cases the fragment distribu-
tions that are formed in the high-energy modulation
approach used in the IMS approach will include frag-
ments from a mixture of precursors that are present.
This complicates the identification and assignments of
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this approach somewhat higher than MS/MS based
methods).
A final note before discussing the data and the map
is associated with analysis of datasets. A major bottle-
neck that comes about from including an IMS separa-
tion is that datasets are much larger than those obtained
without this dimension (additionally there are no com-
mercially available algorithms for analysis). Although
there is an advantage associated with the fact that the
additional peak capacity comes at no additional cost in
time required to acquire data (with and without IMS
separation), there is a disadvantage associated with
computing time associated with analysis.
Example Plots of SCX-LC-IMS-MS Data
Figure 2 shows several representations of various parts
of the multidimensional dataset. We begin by plotting
the recorded ion intensity obtained for bins associated
with the LC and IMS dimension for a single SCX
fraction of one of the samples (Figure 2a). This plot
shows that there is a broad distribution of ions that are
observed from 30 to 100 min. A clear feature of this
plot (Figure 2a) is that peptides co-elute over most of
the LC-separation time. While it is not apparent from
this representation of the data, we note that except for
the leading and trailing edges of the IMS dimension,
multiple ions are observed at essentially every drift
time as well. Examination of these data leaves us with
the impression that even the three-dimensional SCX-
LC-IMS separation is far less than what would be
required to isolate components before introduction into
the mass spectrometer.
An impression about the resolution and peak
capacity associated with these dimensions of separa-
tion can be obtained from a two-dimensional tR(tD)
base-peak plot (Figure 2b) derived from a single
LC-IMS-MS analysis. This plot shows only the most
intense peaks across all flight times. A significant
advantage of this type of plot is that it shows the
importance of including an ion mobility dimension.
Many different ions have identical retention times.
From the widths of peaks in each dimension, and the
range over which they are observed, we estimate the
experimental two-dimensional LC-IMS peak capacity
to be 6000 to 9000.
Figure 2 also shows a plot of the intensities and
positions of peaks as they are projected onto only the
LC axis. This provides additional insight about the
relationship of sample complexity to experimental peak
capacity. In this case essentially all features that are
observable in the LC dimension are comprised of many
peaks.
Reproducibility of Identified Peptide Positions
It is important to assess the reproducibility of peaks.
Analysis of data for assignments obtained from sequen-tial triplicate runs of a single sample shows that peptide
ion peak positions within the multidimensional dataset
are highly reproducible. Along the tR and tD dimen-
sions, the percent relative uncertainty in position (from
three analyses) is 1% and 2%, respectively. A similar
comparison of the same peaks for three different sam-
ples yields a reproducibility of 4.8% and 2% for these
respective dimensions. Note that the position of a peak
in the drift time dimension does not vary for different
samples.
Accumulation of the Plasma Proteome Map
Peaks associated with peptide ions from the SCX-LC-
IMS-MS datasets are identified by combining infor-
mation from the precursor MS spectra with the
CID-MS spectra. Figure 3 shows examples of three
typical CID-MS spectra (at specific values of tSCX, tR,
and tD, for fragment ions; precursor data not shown).
Upon analysis, the overall assignments are consistent
with peaks that correspond to primarily y-type and
b-type ions for three peptide sequences (VSFL-
SALEEYTK, DSVTGTLPK, and VEVVDEER) that are
unique to three different proteins (apolipoprotein
A-I, kallikrein, and troponin I, respectively). These
data and assignments are typical of most of the
features that are assigned in our datasets. We have
focused on these three assignments because they
allow some insight about the dynamic range associ-
ated with the raw data as well as the experiment. The
plots have been normalized and so, as indicated in
the figure, the peaks assigned to apolipoprotein are a
factor of 400 times more intense than those for
troponin I. This is consistent with the large difference
in concentrations expected for these proteins (mg
mL 1 to ng mL 1 for these respective proteins [80]).
The concentration of kallikrein is reported to be in the
 40  g mL 1 [81]. From this, we see that generally
the intensities of assigned features are qualitatively
ordered in a fashion that reflects the concentrations of
proteins (in cases where such data exists). However,
there is a large mismatch associated with the range of
measured intensities compared with the range of
known concentrations. This may reflect the fact that
some low abundance components are falsely as-
signed as we dig into the low-intensity features of our
datasets for database searches. An alternative expla-
nation is that variations in physical properties (e.g.,
ionization efficiency, solubility, and dissociation be-
havior), or unexpected differences in concentration of
some specific peptides from low abundance proteins
(due to biological accumulation or loss), limit the
accuracy of quantitative comparisons.
Analysis of all datasets leads to 57,192 ion assign-
ments (hits). Of these, 37,842 correspond to unique
peptide sequences. Assuming that these sequences
arise from a protein that existed in plasma, this list
leads to 9087 unique protein assignments. Many of
the catalogued proteins have multiple peptide hits.
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peptide hits may vary over the list of proteins. For the
apolipoprotein A-I sequence, analysis of all datasets
leads to 930 hits of 39 different peptides. This corre-
sponds to 88% of the total sequence of the protein.
Only six short peptides and one longer peptide werenot included in the coverage: MK, AK, AR, QR,
LAAR, LNTQ, and AAVLTLAVLFLTGSQAR. Inter-
estingly MK, AK, AR, and QR are not unique and
thus, although we have detected these peptides, it is
not known whether or not they arise from apoli-
poprotein A-I. The LNTQ sequence is not a tryptic
sequence and therefore was not included in our
search algorithm. Additionally, none of these pep-
tides (with the exception of the 17-residue peptide)
would meet one of our search criteria (imposed after
database assignment and used to reduce the number
of false positives—that fragment ions must corre-
spond to cleavage between at least five residues). The
kallikrein and troponin I assignments are based on
six and two hits, respectively. In these cases we find
no evidence for large regions of the sequence. Be-
cause of this, assignments are far less robust (as
discussed below).
Tables 1 and 2 provide a means of illustrating the
structure of the overall map. Note that the tables that
are shown are for example only. The complete maps are
provided as Supplementary Information section in Ta-
bles S1 and S2, respectively (which can be found in the
electronic version of this article). Table 1 is an accumu-
lation of all uniquely assigned peptides and their cor-
responding proteins. It includes the positions (in all
dimensions of the analysis) and intensities of peaks, the
homology scores used to make each assignment, the
corresponding protein, and its accession number. In
total Table S1 contains entries for 37,842 unique peptide
ions. A useful way of understanding the information in
Table S1 comes from the representation of their LC,
IMS, and MS positions as shown in Figure 4. This plot
shows the positions of the 100,000 most intense features
that appear from the triplicate analysis of Sample 1.
Features associated with all eight of the SCX fractions
are included. The arrows represent features that are
associated with specific assignments for four proteins
(the three described in Figure 3 as well as transthyretin).
In this case there are many more positions associated
with the detection of apolipoprotein A-I than with
detection of troponin. Although we have not analyzed
the data in this fashion, knowledge of the positions of
peaks will further corroborate assignments of the other
4™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
Figure 2. (a) Shows a 2D, tR(tD) plot of the raw data (A) for a
single SCX fraction (Sample 3). The plot is obtained by summing
all TOF bins at each tR and tD value. Intensities are represented as
a color map with the most intense level set at 150 counts. The
representation indicates that individual 2D bins are saturated
across a wide range of retention and drift times. (b) Shows the
same data when plotted as a 2D, tR(tD) base-peak diagram. This
plot is obtained by extracting the intensity value obtained for the
most intense m/z value in the MS measurement (extracted for
every tR (tD) position to create the contour plot). The traces below
each contour plot show the ion chromatograms obtained by
integrating all tD bins at each tR for the respective 2D plots. For
more details about the generation of these datasets see text
references and discussion therein.
as be
1256 LIU ET AL. J Am Soc Mass Spectrom 2007, 18, 1249–1264datasets. In addition, the accumulation of data in Table
S1 provides valuable information for future work that
would aim to predict SCX-retention times, LC-retention
times, and mobilities based on sequences and charge
states.
The example shown as Table 2 lists 20 proteins that
are identified from assignments made on data for all
five samples. Those chosen here correspond to the most
robust assignments in that they represent our top 20 in
terms of cumulative hits. In addition to information
about the number of hits, we also include the integrated
ion intensities for the precursor ion peaks that were
assigned (the complete list of proteins with the corre-
sponding number of peptide hits and summed intensity
values can be found in Table S1). The number of
peptide ion assignments (hits) and the summed inten-
Figure 3. The plots on the right show fragmen
been identified based on database assignments (
when the second field region of the split-fiel
sufficient to induce fragmentation. The low-field
precursor ions (acquired in alternating fashion
spectra that are shown are consistent with the
sequences that are unique to the proteins apolip
labels given to fragment ions in the spectra are
preponderance of y-type fragments (generally th
in these studies). The sequences to the left corres
respective proteins and those regions that are
approach are shown in red. Also indicated is
protein and the percentage of the sequence that hsities are highly correlated. For example, a comparisonof the number of peptide hits and integrated intensities
for the extremes listed in Table 2 shows that there is a
factor ofseven times (930/142) more hits, correspond-
ing to nine times (2.2  106/2.4  105) more ion
intensity for the first entry (apolipoprotein A-I) com-
pared with the 20th entry (-1-acid glycoprotein 1
precursor). An additional impression about the number
of times different proteins are identified based on this
approach can be obtained by examining Figure 5. This
analysis shows that 1362 proteins are assigned by at
least 10 peptide hits. This number decays dramatically
as the number of hits increases. For example, only 70
proteins are defined by more than 40 peptide hits.
As a final comment, we note that most of the peaks
in these datasets do not lead to assignments (less than
0.1% of the precursor ion peaks are assigned using
n spectra of three identified peptides that have
xt). These spectra are generated experimentally
ft tube is modulated to high-field conditions
ulation data associated with measurement of the
ughout the entire dataset) is not shown. The
LASALEEYTK, DSVTGTLPK, and VEVVDEER
tein A-I, plasma kallikrein, and troponin I. The
rated by the database assignment and show a
servation for fragments generated at high-fields
to the total amino acid sequences of each of the
red by assignments of peptides based on this
ber of unique peptide ions identified for each
en identified by the analysis. See text for details.tatio
see te
d dri
mod
thro
VSF
opro
gene
e ob
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numthe present criteria). The low fraction of assignments
 acro
1257J Am Soc Mass Spectrom 2007, 18, 1249–1264 MAPPING THE HUMAN PLASMA PROTEOME BY SCX-LC-IMS-MSmay result from several factors: limitations in the
quality of the CID data generated in the drift tube (a
relatively new approach that has not been tested
extensively); substantial overlap of fragments from
multiple different precursor ions that complicates
spectra; and the restriction of assignments to only
tryptic fragments containing up to only one missed
cleavage and no considerations of post-translational
modifications.
Considerations Associated with Detection
of False Positives
Figure 6 shows a representation of Table S2 in terms of
the total number of hits that are obtained for each of the
9087 entries associated with at least one hit. An issue
that arises is which assignments should be trusted as
components that are likely to be detectable with this
type of approach. Examination of these data show that
there is an apparent transition in the curve that occurs
at about 60—essentially the number of proteins that are
assigned using two-dimensional gels [15], comprised of
mostly the high-abundance classical plasma proteins
[3]. Our expectation is that the total number of hits
should be roughly proportional to the protein concen-
tration and size (larger proteins will have more pep-
tides that can be detected). Thus, the transition at
around 60 proteins reflects the fact that the concentra-
tions of many proteins fall just slightly below the
detection limits of the earlier technologies.
Beyond this number, the issue of how many proteins
are detectable in plasma requires that we understand
the threshold for detection in more detail. Probability-
based scoring algorithms are prone to making false
Table 1. Peptide assignments from the integrated analysis of th
Acc. #b Protein nameb Peptide sequence
P02647 Apolipoprotein A-I
precursor (Apo-AI)
(ApoA-I)
DYVSQFEGSALGK
VSFLSALEEYTKK
LLDNWDSVTSTFSK
VSFLSALEEYTK
VSFLSALEEYTKK
P01024 Complement C3
precursor [Contains:
C3a anaphylatoxin]
RIPIEDGSGEVVLSR
SNLDEDIIAEENIVSR
VPVAVQGEDTVQSLTQGD
ENEGFTVTAEGK
SEETKENEGFTVTAEGK
P02774 Vitamin D-binding
protein precursor
(DBP) (Group-
specific component)
(Gc-globulin) (VDB)
VPTADLEDVLPLAEDITNIL
LAQKVPTADLEDVLPLAED
HQPQEFPTYVEPTNDEICE
KFPSGTFEQVSQLVK
SCESNSPFPVHPGTAECCT
aFor a complete list of the 38505 unique peptide ions, see Table S1 in
bProtein accession numbers and names have been obtained from the 
cMost frequently observed peptides for indicated proteins.
dCharge states observed for indicated peptides yielding the highest M
eAverage nested multidimensional retention and drift times as well as
fSummed precursor ion intensities obtained for each peptide assigned
gHighest Mascot ion score obtained for the indicated peptide.assignments [40], even with the additional assignmentcriteria that we described above. Therefore it is worth-
while to examine the false-positive rate in more detail.
This is done by determining the rate of assignments that
are made when a nonsensical protein database is used
[40, 82– 85]. This database was created by inverting all
protein sequences in the Swiss-Prot nonredundant hu-
man database. Estimated false-positive rates range from
6% to 10% from replicate analyses [9].
Figure 6 shows a plot of the number of times that a
protein would be randomly assigned [using a 10%
false-positive rate (the upper end of the range) and
three times this value (30%)]. From this analysis we
observe that a substantial fraction of those proteins that
are assigned based on only a few hits are likely to be
random assignments (Table S2). Briefly, peptide ion hits
(equal to the number of false positives) are removed
randomly from the total protein list. Upon randomly
hitting a protein assignment a number of times equal to
the number of peptide ion hits, it is removed from the
high-confidence protein list. Inspection of the remain-
ing proteins allows one to determine the threshold hit
level for which none of the proteins was removed from
the list. For example, 45% to 88% of assignments based
on a single peptide hit are random (using the 10% and
30% false-positive rate limits, respectively). This num-
ber drops to 12% to 64% of the assignments if two hits
are used. A random assignment rate of fewer than one
in 20 is found at the 30% false positive rate when at least
six hits are used to identify a single protein (note that no
false-positives are predicted at six hits when our 10%
false positive rate is used). From the threshold value of
six, we determine that 2928 of these identifications are
high-confidence assignments. We anticipate that more
low-abundance species will become high-confidence
an plasma samplesa
zd tSCX{tR[tD(m/z)]}
e Intensityf Scoreg
2 2.2 {44.04 [6.79 (701.38)]} 1.07E05 93
3 5.2 {54.26 [5.58 (505.84)]} 1.22E05 91
2 3 {49.43 [7.2 (807.34)]} 1.72E04 89
2 4.9 {63.28 [7.03 (694.15)]} 4.52E05 87
2 6 {52.71 [5.69 (758.44)]} 3.50E03 86
3 4.7 {33.07 [5.79 (543.35)]} 1.52E05 116
2 2.8 {40.26 [7.19 (909.18)]} 3.69E03 106
K 3 2 {39.16 [6.89 (733.77)]} 2.16E04 103
2 3.3 {24.18 [6.58 (641.47)]} 5.95E04 98
3 4.5 {29.01 [6.17 (619.76)]} 1.61E05 96
3 3.7 {92.25 [7.12 (789.88)]} 2.02E05 112
LSK 3 4.1 {85.13 [7.76 (936.6)]} 7.59E04 108
3 7.5 {38.48 [6.87 (903.29)]} 9.51E03 105
3 5.2 {40.65 [5.86 (565.81)]} 8.15E04 90
3 3.9 {23.45 [6.48 (755.97)]} 2.41E04 79
upplementary Information.
-Prot nonredundant human protein database (http://ca.expasy.org/).
ion scores.
alues indicated peptides [tSCX(fraction number), tR(min), tD(ms), m/z].
ss the dataset.e hum
c
GVA
SK
ITNI
AFR
K
the S
Swiss
ascot
m/z vassignments as more experiments are conducted.
Table 2. List of the twenty proteins with the greatest number of peptide hitsa
Acc. #b Protein nameb  hitsc 1d 2 3 4 5  intensitye 1 2 3 4 5
1 P02647 Apolipoprotein A-I precursor 930 218 241 212 112 147 2169900 226637 464912 269388 637943 571020
2 P01024 Complement C3 precursor 928 342 152 209 113 112 1856387 333768 279329 269584 547142 426564
3 P01023 Alpha-2-macroglobulin precursor 686 235 84 149 116 102 1730600 247284 169271 239802 698342 375901
4 P02671 Fibrinogen alpha/alpha-E chain precursor 491 114 102 111 74 90 1054699 90674 165561 118192 424895 255377
5 P04114 Apolipoprotein B-100 precursor 454 226 43 106 29 50 721764 196098 70513 138835 75778 240540
6 P02675 Fibrinogen beta chain precursor 445 104 118 103 52 68 991485 100976 168098 132819 283699 305893
7 P01028 Complement C4 precursor 425 86 115 88 59 77 847398 77866 199007 123065 226630 220830
8 P02679 Fibrinogen gamma chain precursor 369 67 105 77 35 85 647453 57521 121342 95082 104062 269446
9 P02652 Apolipoprotein A-II precursor 331 60 60 93 64 54 1102974 45471 147711 129048 580378 200366
10 P02774 Vitamin D-binding protein precursor 274 81 78 58 26 31 601450 75345 138687 79062 142727 165629
11 P02790 Hemopexin precursor 242 87 47 50 13 45 641994 96719 101316 78435 72161 293363
12 P00450 Ceruloplasmin precursor 210 63 48 49 20 30 412353 92774 92812 69970 41018 115779
13 P08603 Complement factor H precursor 196 59 35 39 49 14 331465 52557 48127 58215 133929 38637
14 Q14624 Inter-alpha-trypsin inhibitor heavy chain
H4 precursor
189 62 24 52 29 22 265317 42041 44009 65784 71135 42348
15 P00734 Prothrombin precursor 177 69 29 48 12 19 293207 63472 36126 65730 49657 78222
16 P01042 Kininogen precursor 165 43 44 31 28 19 306598 43192 72474 46571 78245 66116
17 P02749 Beta-2-glycoprotein I precursor 152 52 38 32 12 18 281490 50874 82110 38698 19100 90708
18 P00751 Complement factor B precursor 151 45 21 30 34 21 363982 48586 19614 30182 207127 58473
19 P02765 Alpha-2-HS-glycoprotein precursor 150 22 47 35 13 33 235437 20094 54310 40283 69528 51222
20 P02763 Alpha-1-acid glycoprotein 1 precursor 142 27 38 27 30 20 241833 24242 23594 27111 95228 71658
Totals 7107 2062 1469 1599 920 1057 15097786 1986191 2498923 2115856 4558724 3938092
aFor a complete list of proteins identified from protein database searches see Table S2 in the Supplementary Information.
bProtein accession numbers and names have been obtained from the Swiss-Prot nonredundant human protein database (http://ca.expasy.org/sprot/).
cTotal number of peptide ion determinations for each protein.
dSample number. Each sample was analyzed in triplicate (see text for details).
eSummed precursor ion intensity obtained from all of the peptide ion assignments.
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1259J Am Soc Mass Spectrom 2007, 18, 1249–1264 MAPPING THE HUMAN PLASMA PROTEOME BY SCX-LC-IMS-MSAs a final note, in a preliminary set of experiments
using a substantially longer drift tube (3 m) that is
operated under conditions that provide a factor of
three to four times improvement in peak capacity (in
the drift time dimension) [9], we find substantial in-
creases in the MASCOT scores for peptides associated
with abundant proteins (in direct comparisons of the
same sample analyzed on different instruments). This
result is consistent with the idea that simultaneous
elution of multiple components interferes with assign-
ing features. At this stage, comparisons can only be
made for abundant species that are already known to be
present in plasma. We are currently in the process of
improving the sensitivity of this instrument so that this
method can also be used to confirm (or dispute) the
assignments we have made for lower abundance com-
ponents.
Features of the Plasma Proteome Map
It is instructive to consider the types of proteins ob-
served in the high-confidence list. Anderson, Smith,
and their collaborators have previously assessed the
content of plasma based on considerations of Gene
Ontology (GO) [15, 21, 39]. In general terms, this
provides a representation of where in the cell different
Figure 4. A 3D dot plot representation of the po
m/z dimensions) that are obtained from the 1 1
triplicate LC-IMS-MS analyses of all SCX fractio
plot are the positions for 10,000 features that
indicate some of the precursor ion positions of p
representation is intended to provide the reader
abundant protein in plasma (such as apolipoprot
and therefore upon comparison there should be
low-abundance protein (such as troponin I) may
significant uncertainty about its detection. See tproteins are distributed. Figure 7 shows the percentageof each GO component in the entire Swiss-Prot database
as well as the percentage of each component in the
current plasma map. The percentages are significantly
different for several key components (e.g., the extracel-
lular, cytoplasmic, and nuclear components). The dif-
ns of peaks (in the retention time, drift time, and
st intense features (orange) observed during the
ssociated with Sample 1. Superimposed on the
been assigned to peptides (blue). The arrows
es identified for the four proteins labeled. This
the impression that the possible existence of an
-I) could be tested at many positions in the map
e ambiguity regarding its detection; whereas, a
epresented at only a single position, leading to
r discussion.
Figure 5. Bar graph showing the total number of proteins as a
function of observed peptide hits per protein. The numbers for all
assigned proteins are given in the Supplementary Informationsitio
05 mo
ns a
have
eptid
with
ein A
littl
be r(Table S2).
1260 LIU ET AL. J Am Soc Mass Spectrom 2007, 18, 1249–1264ferences further corroborate the notion that the map is
not composed of random assignments. If it were, the
percentages of each GO component in the plasma map
would more closely mimic those in the protein data-
Figure 6. The top graph shows the percentage of false positive
assignments for each peptide hit level from the random peptide
hit removal analysis (see text for description) using the 10% (red)
and 30% (blue) false positive rate estimates. Note that the 30%
limit is a factor of three times greater than the upper limit of the
(6% to 10%) range established in the false-positive rate estimate
and is included to provide a feeling about an extreme limit (see
text for discussion). The arrow shows the peptide hit threshold for
which no proteins were randomly removed at six hits and above
(at a 10% false positive rate) and less than 1 in 20 protein
assignments is considered a false positive (from the 30% trace).
The bottom graph shows a log–log plot of the total number of
peptide hits for each identified protein (Table S1, Supplementary
Information). The dashed line shows the peptide hit level for the
100th protein (35 hits). The 6-hit threshold (obtained from the top
plot) is also shown with an arrow which indicates the cutoff
between the 2928 proteins that are defined as high-confidence
assignments (to the left of the threshold) and the 6159 low-
confidence assignments (to the right of the threshold). An addi-
tional arrow at protein number 60 indicates the number of
proteins that were detected using 2D gel techniques, most of
which are classical plasma proteins (see text). The change in slope
near this value reflects a transition in concentrations between
these more abundant components (mostly classical plasma pro-
teins) and those that arise from tissue leakage.base. Perhaps a better comparison is to look at theprotein makeup by including a weighting factor for
each protein based on the number of peptide ion hits.
Figure 7c shows the change in GO component percent-
ages when the protein list is weighted by the number of
peptide hits used to represent it. A noticeable increase
in the percentage (13% to 28%) of the extracellular
component is observed with a decrease in the overall
percentage (39% to 28%) of the membrane component.
This is consistent with the greater number of observa-
tions of classical plasma proteins.
Figure 7. Major gene ontology (GO) component percentages for
the entire human proteome (a), the plasma proteome generated
from IMS-MS experiments (b), as well as the proteome map
weighted by the number of protein hits (c). See text for discussion.
Table 3. List of top 26 proteins identified with more than 100 hits in the current analysis and the overlap with the previous SCX-LC-IMS-MS, the 1175 nonredundant, and the HUPO
core datasetsa
Acc. #b Protein nameb  hitsc 1d 2 3 4 5
SCX-LC-
IMS-Mse 1175 NRf HUPOg
1 P02647 Apolipoprotein A-I precursor 930 218 241 212 112 147 18 6 78
2 P01024 Complement C3 precursor 928 342 152 209 113 112 17 4 246
3 P01023 Alpha-2-macroglobulin precursor 686 235 84 149 116 102 16 5 207
4 P02671 Fibrinogen alpha/alpha-E chain precursor 491 114 102 111 74 90 9 3 65
5 P04114 Apolipoprotein B-100 precursor 454 226 43 106 29 50 10 4 317
6 P02675 Fibrinogen beta chain precursor 445 104 118 103 52 68 7 3 51
7 P01028 Complement C4 precursor 425 86 115 88 59 77 12 5 155
8 P02679 Fibrinogen gamma chain precursor 369 67 105 77 35 85 10 1 50
9 P02652 Apolipoprotein A-II precursor 331 60 60 93 64 54 0 4 17
10 P02774 Vitamin D-binding protein precursor 274 81 78 58 26 31 5 5 47
11 P02790 Hemopexin precursor 242 87 47 50 13 45 4 3 86
12 P00450 Ceruloplasmin precursors 210 63 48 49 20 30 2 4 131
13 P08603 Complement factor H precursor 196 59 35 39 49 14 1 4 125
14 Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 189 62 24 52 29 22 2 5 86
15 P00734 Prothrombin precursor 177 69 29 48 12 19 6 5 69
16 P01042 Kininogen precursor 165 43 44 31 28 19 1 8 52
17 P02749 Beta-2-glycoprotein I precursor 152 52 38 32 12 18 3 4 73
18 P00751 Complement factor B precursor 151 45 21 30 34 21 2 4 76
19 P02765 Alpha-2-HS-glycoprotein precursor 150 22 47 35 13 33 2 4 65
20 P02763 Alpha-1-acid glycoprotein 1 precursor 142 27 38 27 30 20 3 3 45
21 P06727 Apolipoprotein A-IV precursor 130 45 39 22 11 13 3 5 45
22 P04217 Alpha-1B-glycoprotein precursor 121 35 21 19 20 26 0 3 43
23 P01008 Antithrombin-III precursor 120 61 12 32 6 9 3 4 67
24 P01011 Alpha-1-antichymotrypsin precursor 117 54 16 23 9 15 0 4 76
25 P19827 Inter-alpha-trypsin inhibitor heavy chain H1 117 29 32 16 23 17 1 5 56
26 P10909 Clusterin precursor 106 38 17 28 13 10 0 4 53
Totals 7818 2324 1606 1739 1002 1147 137 109 2381
aFor a complete list of proteins that overlap with the previous IMS, 1175 nonredundant, and HUPO datasets, see Tables S3, S4, and S5 in the Supplementary Information.
bAccession numbers and names have been obtained from the Swiss-Prot human protein database (http://ca.expasy.org/sprot/). Note: names are limited to the first 30 characters, including spaces.
cTotal number of peptide ion determinations for each protein.
dSample number. Each sample was analyzed in triplicate. [See text for details.]
eNumber of peptides hits from the previous SCX-LC-IMS-MS analysis of human plasma. See reference 9 for details.
fNumber of peptide hits from the 1175 nonredundant protein list compiled by Anderson and coworkers. See reference 15 for details.
gNumber of distinct peptides listed for the high confidence HUPO dataset that includes 3020 total proteins. See reference 25 for details.
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1262 LIU ET AL. J Am Soc Mass Spectrom 2007, 18, 1249–1264Comparison of this Map with Others
As a check of consistency, it is useful to compare the
high-confidence list of proteins with other maps of
plasma. We arbitrarily began by comparing 26 proteins
that we observed with at least 100 hits to our previous
SCX-LC-IMS-MS analysis in Table 3 [9]. Although there
is substantial variability in the number of peptide hits,
most (22) of the 26 proteins are detected in the previous
study. A comparison to our complete list observed
previously shows that 252 of the 438 proteins reported
previously are reported as high-confidence assignments
in the current studies. The overlap can be found in the
Supplementary Information (Table S3).
A second comparison involves the 1175 nonredun-
dant dataset compiled by Anderson and coworkers [15].
Our top 26 proteins all overlap with the Anderson list
(Table 3). Their analysis determined that only 46 pro-
teins were observed from all sources. We note that all 46
of those proteins are observed as high-confidence as-
signments in our present study. Interestingly, they are
all found in our top 100 proteins. A more detailed
comparison of the 2928 high-confidence protein assign-
ments with the 1175 protein list shows that 321 proteins
are found in both (see Table S4).
Finally, we have compared some of our maps to
some data reported by the plasma proteome project
(PPP). In the case of the 26 proteins in Table 3, all are
also reported in the PPP dataset. It is more difficult to
compare with the complete PPP database because the
system of protein accession numbers is from multiple,
independently curated databases. Comparison by name
and accession number (a by-hand comparison) of our
top 300 proteins with the 3020 core dataset provided by
HUPO shows that 185 are found in both datasets
(provided as Table S5 in the Supplementary Informa-
tion).
Considerations of Dynamic Range
Commercial MS instruments have a dynamic range of
102-105 [86 –90]. The inclusion of an IMS dimension is
expected to improve this due to the removal of chemical
noise [8]. From assignments that fall at the threshold
associated with high-confidence assignments, we can
assess the expected dynamic range of this system. As
examples, troponin I, prostatic acid phosphatase, and
thyroxine-binding globulin protein each were observed
with five peptide hits (just below the high-confidence
threshold). The concentrations of these proteins are 1.0,
1.7, and 14.1 ng-mL1, respectively [90]. The proteins
thyroglobulin, tissue-type plasminogen activator, and
plasma kallikrein are observed 21, eight, and nine times,
respectively, in the plasma map. These proteins have
nominal plasma concentrations of 19.0, 5.5, and 55.0
ng-mL1, respectively. This analysis suggests that for
most species we might expect an estimated lower limit
for identification in the low ng-mL1 range; this would
suggest an experimental dynamic range of 105 to 106.Within the high-confidence dataset, a single interleu-
kin (reported as IL-16 precursor in Table S1, but only
represented with hits in the body of the protein) was
observed (15 peptide ion hits across seven unique
regions of sequence). Based on our confidence analysis,
we expect this to be a reproducible signal with this
approach. However, clearly some additional caution
should be taken in considering this assignment (as with
any other assignment for a protein that is known to
exist in extremely low abundances). Assuming an IL-16
protein concentration of 10 pg-mL1 (within plasma,
and no sample loss during workup), would require
detection of 5 pg or 75 attomol. This approaches the
ultimate measured detection limit for this instrumenta-
tion [54]. We include the result in our high-confidence
list because it meets the imposed criteria. However, we
urge the users of this map to approach this and other
assignments for species that are known to exist at very
low abundances cautiously.
Summary and Conclusions
A multidimensional SCX-LC-IMS-MS experiment com-
bined with a database assignment approach has been
used to generate a plasma proteome map. Triplicate
analyses of plasma from five healthy people results in
assignment of 9087 proteins of which 2928 are expected
to be reproducibly detected with this experimental
approach. The map contains information about protein
accession numbers and names, peptides used for as-
signments, as well as peak positions within the multi-
dimensional space and intensities. Comparison of these
assignments with those found in other maps suggests
good agreement for the most abundant components.
There is reasonable agreement about the first several
hundred proteins in our map with other datasets.
Beyond this level, many components in the map devel-
oped here appear to be unique to our approach; addi-
tionally, this analysis does not assign many features
that are included in other summaries.
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